Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications

[1]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[2]  J. Wang-Rodriguez,et al.  Expression signatures that correlated with Gleason score and relapse in prostate cancer. , 2007, Genomics.

[3]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[4]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[5]  P. Stafford,et al.  Three methods for optimization of cross-laboratory and cross-platform microarray expression data , 2007, Nucleic acids research.

[6]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Amy Blase,et al.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.

[8]  M. Menon,et al.  Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine , 2007, Proceedings of the National Academy of Sciences.

[9]  J. Foekens,et al.  HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[11]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[12]  Gary Hardiman,et al.  Microarrays Technologies 2006: an overview. , 2006, Pharmacogenomics.

[13]  Lei Wang,et al.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.

[14]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[15]  W. Schulz,et al.  Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. , 2006, Endocrine-related cancer.

[16]  Hanlee P. Ji,et al.  The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. , 2006, Nature biotechnology.

[17]  P. Febbo,et al.  Defining aggressive prostate cancer using a 12-gene model. , 2006, Neoplasia.

[18]  Daniel W Lin,et al.  Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .

[21]  J. Stanford,et al.  The Distribution of Serum Prostate‐Specific Antigen Levels Among American Men: Implications for Prostate Cancer Prevalence and Screening , 2006, The Prostate.

[22]  Francisco Azuaje,et al.  An assessment of recently published gene expression data analyses: reporting experimental design and statistical factors , 2006, BMC Medical Informatics Decis. Mak..

[23]  Robin B. Gasser,et al.  A hitchhiker's guide to expressed sequence tag (EST) analysis , 2006, Briefings Bioinform..

[24]  H. Lilja,et al.  Immunohistochemical detection of cysteine‐rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland , 2006, The Prostate.

[25]  Christina L. Zheng,et al.  Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. , 2006, Cancer research.

[26]  Michael Q. Zhang,et al.  Profiling alternatively spliced mRNA isoforms for prostate cancer classification , 2006, BMC Bioinformatics.

[27]  M. Wirth,et al.  Quantitative multi‐gene expression profiling of primary prostate cancer , 2006, The Prostate.

[28]  Michael M Lieber,et al.  PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Jun Yao,et al.  SAGE and related approaches for cancer target identification. , 2006, Drug discovery today.

[30]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[31]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[32]  Mitsutoshi Nakamura,et al.  High Expression of a New Marker PCA-1 in Human Prostate Carcinoma , 2005, Clinical Cancer Research.

[33]  W. Gerald,et al.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy , 2005, Cancer.

[34]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[35]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[36]  Rajiv Dhir,et al.  Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors , 2005, BMC Cancer.

[37]  K. Do,et al.  Combined laser capture microdissection and serial analysis of gene expression from human tissue samples , 2005, Modern Pathology.

[38]  J. Brenton,et al.  Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt , 2005, Breast Cancer Research.

[39]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[41]  Inge Jonassen,et al.  Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. , 2005, International journal of oncology.

[42]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[43]  C. Cooper,et al.  Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer , 2004, British Journal of Cancer.

[44]  Gary Hardiman,et al.  Microarray platforms--comparisons and contrasts. , 2004, Pharmacogenomics.

[45]  Yusuke Nakamura,et al.  Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer , 2004, Cancer Research.

[46]  P. Nelson,et al.  Characterization and comparative analyses of transcriptomes from the normal and neoplastic human prostate , 2004, The Prostate.

[47]  Martina Tinzl,et al.  DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. , 2004, European urology.

[48]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. Tangen,et al.  SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[52]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[53]  Jian-Bing Fan,et al.  A versatile assay for high-throughput gene expression profiling on universal array matrices. , 2004, Genome research.

[54]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[55]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[57]  J. Wang-Rodriguez,et al.  In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Pardee,et al.  Analysing differential gene expression in cancer , 2003, Nature Reviews Cancer.

[59]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[60]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[61]  K. Gish,et al.  Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. , 2003, Cancer research.

[62]  Yingdong Zhao,et al.  Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer by cDNA Microarray Analysis , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[63]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[64]  Ronglai Shen,et al.  Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. , 2002, The American journal of pathology.

[65]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[66]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[67]  T. Barrette,et al.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.

[68]  M. Rubin,et al.  Alpha-Methylacyl-CoA Racemase: A Novel Tumor Marker Over-expressed in Several Human Cancers and Their Precursor Lesions , 2002, The American journal of surgical pathology.

[69]  Matthias Kretzler,et al.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.

[70]  George Vasmatzis,et al.  Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. , 2002, Cancer research.

[71]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[72]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[73]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[74]  T. Stamey,et al.  Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. , 2001, The Journal of urology.

[75]  I. Pastan,et al.  GDEP, a new gene differentially expressed in normal prostate and prostate cancer † , 2001, The Prostate.

[76]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[77]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[78]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[79]  M. Schober,et al.  Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. , 2001, Cancer research.

[80]  David Handelsman,et al.  Identification of differentially expressed genes in organ‐confined prostate cancer by gene expression array , 2001, The Prostate.

[81]  X. Estivill,et al.  PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks , 2001, Oncogene.

[82]  L. Cazares,et al.  Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. , 2000, Cancer research.

[83]  W. Zhang,et al.  PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. , 2000, Cancer research.

[84]  M. Augustus,et al.  PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[85]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[86]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[87]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[88]  佐治 重衡,et al.  What's going on 乳癌 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. Cancer Cell. 2004;5:607-16. PMID:15193263--術後補助療法におけるタモキシフェンへの反応性は2つの遺伝子レベルの測定によって予測しうることを示した論文 , 2005 .

[89]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[90]  M. Rubin,et al.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. , 2001, Neoplasia.

[91]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.